BGBIO
vs
Oslo OBX
Over the past 12 months, BGBIO has underperformed Oslo OBX, delivering a return of -73% compared to the Oslo OBX's 16% growth.
Stocks Performance
BGBIO vs Oslo OBX
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
FR |
Pharnext SCA
OTC:PNEXF
|
||
US |
Abbvie Inc
NYSE:ABBV
|
||
US |
Amgen Inc
NASDAQ:AMGN
|
||
US |
Gilead Sciences Inc
NASDAQ:GILD
|
||
US |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
||
US |
E
|
Epizyme Inc
F:EPE
|
|
AU |
CSL Ltd
ASX:CSL
|
||
US |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
||
US |
S
|
Seagen Inc
F:SGT
|
|
NL |
argenx SE
XBRU:ARGX
|
Performance Gap
BGBIO vs Oslo OBX
FR |
Pharnext SCA
OTC:PNEXF
|
||
US |
Abbvie Inc
NYSE:ABBV
|
||
US |
Amgen Inc
NASDAQ:AMGN
|
||
US |
Gilead Sciences Inc
NASDAQ:GILD
|
||
US |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
||
US |
E
|
Epizyme Inc
F:EPE
|
|
AU |
CSL Ltd
ASX:CSL
|
||
US |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
||
US |
S
|
Seagen Inc
F:SGT
|
|
NL |
argenx SE
XBRU:ARGX
|
Performance By Year
BGBIO vs Oslo OBX
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
FR |
Pharnext SCA
OTC:PNEXF
|
||
US |
Abbvie Inc
NYSE:ABBV
|
||
US |
Amgen Inc
NASDAQ:AMGN
|
||
US |
Gilead Sciences Inc
NASDAQ:GILD
|
||
US |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
||
US |
E
|
Epizyme Inc
F:EPE
|
|
AU |
CSL Ltd
ASX:CSL
|
||
US |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
||
US |
S
|
Seagen Inc
F:SGT
|
|
NL |
argenx SE
XBRU:ARGX
|
Competitors Performance
Bergenbio ASA vs Peers
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
HR |
C
|
CROBEX
INDX:CRBEX
|
|
SA |
T
|
Tadawul All Share
INDX:TASI
|
|
TH |
S
|
SET Index
INDX:SET
|
|
ID |
J
|
Jakarta Composite Index
INDX:JKSE
|
|
GR |
A
|
Athens General Composite
INDX:ATG
|
|
BR |
B
|
BOVESPA
INDX:BVSP
|
|
AR |
S
|
S&P Merval
INDX:MERV
|
|
MX |
M
|
Mexico S&P/BMV IPC
INDX:MXX
|
|
CZ |
P
|
PX Prague Stock Index
INDX:PX
|
|
RU |
M
|
MOEX Russia
INDX:IMOEX
|
Bergenbio ASA
Glance View
BerGenBio ASA engages in the development of biopharmaceutical product for cancer therapy. The company is headquartered in Bergen, Hordaland. The company went IPO on 2017-04-07. The firm's business portfolio comprises such development stage products as oral axillary lymphoscintigraphy (AXL) kinase inhibitors, small molecule AXL inhibitors, and antibody programs. Its flagship product is BGB324, an orally avaliable small molecule AXL kinase inhibitor. Inhibition of AXL kinase activity addresses an important mechanism in the evolution of cancer cell in terms of its aggressiveness, and focuses on creation of therapeutic options for cancer patients. The firm also performs a range of clinical trials for interested patients, primarily affected with acute myeloid leukemia and non-small cell lung cancer.